Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer

Kimura,Michio; Usami,Eiseki; Iwai,Mina; Go,Makiko; Teramachi,Hitomi; Yoshimura,Tomoaki

doi:10.3892/mco.2016.1020

Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer

Authors:
- Michio Kimura
- Eiseki Usami
- Mina Iwai
- Makiko Go
- Hitomi Teramachi
- Tomoaki Yoshimura
View Affiliations

Affiliations: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki‑shi, Gifu 503‑8502, Japan, Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu‑shi, Gifu 501‑1196, Japan
Published online on: September 15, 2016 https://doi.org/10.3892/mco.2016.1020
Pages: 635-640

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Regorafenib and trifluridine/tipiracil combination tablet regimens are standard third‑line or later treatments for advanced and recurrent colorectal cancer with no significant difference in efficacy. The present study aimed to compare the cost-effectiveness of using regorafenib vs. the trifluridine/tipiracil combination tablet. The expected cost was calculated based on data from patients with advanced and recurrent colorectal cancer who were treated with regorafenib or trifluridine/tipiracil combination tablet. The median survival time (MST) from the CORRECT and the RECOURSE study was used to evaluate the therapeutic efficacy of the regimens. The cost‑effectiveness ratio was calculated from the expected cost and MST for the two regimens. The expected cost per patient for the regorafenib and the trifluridine/tipiracil combination tablet regimen was ¥705,330.3 and ¥371,198.7, respectively, and the cost‑effectiveness ratio was ¥110,207.9/MST and ¥52,281.5/MST, respectively. In conclusion, the findings of the present study demonstrated that the trifluridine/tipiracil combination tablet regimen is more cost‑effective compared with the regorafenib regimen.

View Figures

View References

1	Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
2	Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011. View Article : Google Scholar : PubMed/NCBI
3	Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski P: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
4	Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, Ubel PA and Schnipper LE: American Society of Clinical Oncology: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol. 27:3868–3874. 2009. View Article : Google Scholar : PubMed/NCBI
5	Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF and Flowers CR: First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis. J Clin Oncol. 33:1112–1118. 2015. View Article : Google Scholar : PubMed/NCBI
6	Carter HE, Zannino D, Simes R John, Schofield DJ, Howard K, Zalcberg JR, Price TJ and Tebbutt NC: The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. Eur J Cancer. 50:535–543. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ruiz-Millo O, Albert-Mari A, Sendra-Garcia A and Jimenez-Torres NV: Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. J Oncol Pharm Pract. 20:341–350. 2014. View Article : Google Scholar : PubMed/NCBI
8	Díaz-Rubio E, Pietrantonio F and de Braud F: Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. Oncologist. 17:1426–1428. 2012. View Article : Google Scholar : PubMed/NCBI
9	Rinaldi F, George E and Adler AI: NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. Lancet Oncol. 13:233–234. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tappenden P, Jones R, Paisley S and Carroll C: The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer. 43:2487–2494. 2007. View Article : Google Scholar : PubMed/NCBI
11	Shiroiwa T, Motoo Y and Tsutani K: Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther. 14:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
12	Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS and Go WY: PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI
13	Nomura H, Nagai S, Shinohara T, Iwashita M, Yajima M and Takatoya S: Compared medical costs of treating ovarian cancer patients with weekly paclitaxel, carboplatin (TC) chemotherapy. Gan To Kagaku Ryoho. 34:1091–1094. 2007.(In Japanese). PubMed/NCBI
14	Inage S, Ise Y, Obayashi M, Katayama S and Gemma A: Cost-effectiveness analysis comparing carboplatin and weekly paclitaxel with cisplatin and docetaxel in the treatment of advanced non-small cell lung carcinoma. Gan To Kagaku Ryoho. 37:2093–2100. 2010.(In Japanese). PubMed/NCBI
15	Kurihara T, Kobayashi M, Kogo M, Yoneyama K, Ito N, Sunaga T, Konishi K, Imawari M, Tobe T and Kiuchi Y: Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer. Gan To Kagaku Ryoho. 37:659–664. 2010.(In Japanese). PubMed/NCBI
16	Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
17	Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015. View Article : Google Scholar : PubMed/NCBI
18	Pharmaceutical Society, . Insurance drug encyclopedia. Jiho, Tokyo: Pharmaceutical Society; 2012
19	Kawakami Y: Medical fee points table. 35th. Social Insurance Institute; Tokyo: 2008
20	Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312. 2013. View Article : Google Scholar : PubMed/NCBI
21	US Department Of Health And Human Services, . Common terminology criteria for adverse events (CTCAE) version 4.0. United States: National Cancer Institute; 2009, http://www. acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5X7.pdf
22	Goldstein DA, Ahmad BB, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF and Flowers CR: Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol. 33:3727–3732. 2015. View Article : Google Scholar : PubMed/NCBI
23	Go M, Ikagawa M, Kimura M, Iwai M, Usami E, Yoshimura T and Yasuda K: Awareness of adverse events and health-related quality of life in outpatients receiving molecular targeted drugs for lung cancer patients. J Jpn Soc Hosp Pharm. 51:1462–1466. 2015.(In Japanese).